Further, in vitro combination treatment with carboplatin, paclitaxel, and low concentration of SMAC-mimetic resulted in synergistic effects that were greater when SMAC-mimetic is administered sequentially, instead of simultaneously, with carboplatin in both high and low Caspase 8 ovarian cancer cells. Here, CASP8 is linked to ovarian carcinoma.